Sells Revuforj for acute leukemia and Niktimvo for chronic graft-versus-host disease to specialty distributors and pharmacies, while developing additional cancer medicines.
10-K for FY2025, filed Feb 26, 2026Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the…View ↗
Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August…View ↗
The Company sells Revuforj to specialty distributors and specialty pharmacies, or collectively, Customers. These Customers subsequently…View ↗
Specialty distributors and pharmacies buy Revuforj; sales are counted when the product is delivered, and payment terms are no longer than one year. Syndax also receives its share of Niktimvo profits as sales and related costs occur, plus license payments, milestones and royalties tied to contract events or sales.
10-K for FY2025, filed Feb 26, 2026The Company sells Revuforj to specialty distributors and specialty pharmacies, or collectively, Customers. These Customers subsequently…View ↗
The Company recognizes revenue from product sales at the point Customers obtain control of the product, which generally occurs upon…View ↗
In accordance with Topic ASC 808, Collaboration Arrangements, Incyte has been identified as the principal in product sales, therefore, we…View ↗
We enter into license agreements for the development and commercialization of our product candidates. License agreements may include…View ↗
Development Milestone Payments: The Company evaluates whether milestones are considered probable of being reached and estimates the amount…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$172.4M
10-K for FY2025, filed Feb 26, 2026
$172.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product revenue
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
72% |
Net product revenue, FY2025
$124.8M Sources
|
Sold outright |
|
Collaboration revenue
|
25% |
Collaboration revenue, FY2025
$42.4M Sources
|
|
|
Milestone revenue
Licensed
|
3.0% |
Milestone revenue, FY2025
$5.1M Sources
|
Licensed |
Specialty distributors and specialty pharmacies buy Revuforj from Syndax and resell it to healthcare providers, patients and other pharmacies. Syndax handles Revuforj sales through its own team and third parties, co-commercializes Niktimvo with Incyte, and works with Incyte on axatilimab commercialization globally.
10-K for FY2025, filed Feb 26, 2026The Company sells Revuforj to specialty distributors and specialty pharmacies, or collectively, Customers. These Customers subsequently…View ↗
Sales and MarketingView ↗
In late January 2025, we launched Niktimvo for commercial sale in the U.S. in partnership with Incyte and in accordance with the…View ↗
No. It lost $285.4M in FY2025.
Growing. Revenue grew 23% in 4 years, from $139.7M in FY2021 to $172.4M in FY2025, about 5% a year.
From development to commercial sales
The older report described revumenib and axatilimab as clinical-stage candidates; the latest describes Revuforj and Niktimvo as approved medicines and reports their commercial launches.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our two lead product candidates…View ↗
We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved…View ↗
In late November 2024, we launched Revuforj for commercial sale in the United States. In December 2024, revumenib was added to the NCCN…View ↗
In late January 2025, we launched Niktimvo for commercial sale in the U.S. in partnership with Incyte and in accordance with the…View ↗
Loading...